about
Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi.Old drugs--new usesGlibenclamide, a blocker of K+(ATP) channels, shows antileishmanial activity in experimental murine cutaneous leishmaniasisLem3p is essential for the uptake and potency of alkylphosphocholine drugs, edelfosine and miltefosine.Current challenges in treatment options for visceral leishmaniasis in India: a public health perspectiveMiltefosine for visceral and cutaneous leishmaniasis: drug characteristics and evidence-based treatment recommendationsDevelopment of miltefosine as an oral treatment for leishmaniasisMiltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasisClinical status of agents being developed for leishmaniasisProteomic and genomic analyses of antimony resistant Leishmania infantum mutantDiagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH).Novel compounds active against Leishmania major.Treatment of visceral leishmaniasis.Clinical and experimental advances in treatment of visceral leishmaniasis.Visceral leishmaniasis in mice devoid of tumor necrosis factor and response to treatment.Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis.Identification of phospholipid species affected by miltefosine action in Leishmania donovani cultures using LC-ELSD, LC-ESI/MS, and multivariate data analysis.Treatment options for visceral leishmaniasis.Oral miltefosine for the treatment of Indian visceral leishmaniasis.Treatment of visceral leishmaniasis: a review of current treatment practices.Species-directed therapy for leishmaniasis in returning travellers: a comprehensive guideNew challenges in the epidemiology and treatment of visceral leishmaniasis in periurban areas.Visceral leishmaniasis in Malta--an 18 year paediatric, population based studyTherapeutic switching in leishmania chemotherapy: a distinct approach towards unsatisfied treatment needs.Progress in the treatment of a neglected infectious disease: visceral leishmaniasis.Optimal dosing of miltefosine in children and adults with visceral leishmaniasis.Miltefosine to treat leishmaniasis.Miltefosine: oral treatment of leishmaniasis.Limited activity of miltefosine in murine models of cryptococcal meningoencephalitis and disseminated cryptococcosis.Miltefosine--discovery of the antileishmanial activity of phospholipid derivatives.Mechanisms of action of lysophospholipid analogues against trypanosomatid parasites.Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed clinical risk management.Possible mechanism of miltefosine-mediated death of Leishmania donovani.Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients.Therapeutic options for visceral leishmaniasis.Leishmania dihydroxyacetonephosphate acyltransferase LmDAT is important for ether lipid biosynthesis but not for the integrity of detergent resistant membranes.Identification and Characterization of miRNAs in Response to Leishmania donovani Infection: Delineation of Their Roles in Macrophage DysfunctionCurrent diagnosis and treatment of visceral leishmaniasis.Co-infection of visceral leishmaniasis and HIV-1: a surviving case in China and review of treatment strategies.Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice.
P2860
Q24538777-506435C5-23E5-49A9-AF69-46F2D61090F2Q24650207-43EC5C85-F5F7-4130-A9FA-50D8E70FA1AAQ24674183-A3844F52-8F2D-4626-A1E1-9DD7D1FBFAF6Q27930460-532916CC-51FF-43D4-B5A8-F5A33D8E33B0Q28073426-1CEDDF31-C733-4C76-A6CF-851259728255Q28088410-76445437-4B9F-4416-876D-046D1234407AQ28242586-3A50A7D3-D718-4071-8150-88043B7CB983Q28271849-0CC6584F-3BD7-4298-BCB9-7252EBE7A240Q28279390-010A6D71-DD0C-47CC-B43E-714D2D03A0C3Q28535444-BEE080F3-9599-4C8B-BA6C-46DD1DADB165Q30275257-A99F556B-5AD0-4BBB-B0DB-9461B8542172Q30807168-2F9516B4-C3D1-4E99-91E5-38D9AF4CBBA1Q33929849-DCD5A373-0224-4CA6-9E80-197FCB36B1CFQ33982648-715A43F1-3E7D-4DAE-BE47-AB6DAAEBA0F4Q34005000-14F1E202-27D4-4EF8-BA26-6869C5BEA90EQ34024861-494441CA-E399-4B09-B773-5B239A4A4E9EQ34069469-83003B53-5FC0-41F2-861F-BE6018065ADCQ34510966-6B81B10E-D465-47C2-BB55-A71E016CE7C8Q34531203-BDD7BAD9-B68A-465A-B225-E2A4072B282DQ34768497-E950AAFF-D455-482C-B2AB-A61CF0C06065Q35160905-824730EB-3C87-409D-B91D-8338B16EA948Q35219247-B59FE15C-12E1-4482-AEAC-0BBCE3332B8AQ35266494-E85DEF1D-250F-49F1-82FD-35A9F739DDACQ35606296-2D2326C1-AEC7-445F-8E1D-C4FA324E84A7Q35917392-3DB7FAFD-F3E6-4206-A8C1-68F7A5636284Q36086339-0B5294F2-2940-4E4A-AAF1-07429A807BD0Q36192769-48184AB9-40BA-4C98-9E9D-198CAED69B1CQ36441483-7104A648-EF06-40A6-9AC9-DEC4CA7659ADQ36558539-0519C0BE-9269-4447-80B5-3315D7E560C4Q36564101-CF7A73B6-2257-4CAA-9FA0-55F47390CAF1Q36576096-B23152D0-7496-43F1-B3DC-9B921C506914Q36645795-65077247-D435-4EEE-A749-297F623664C4Q36669276-8EC51FD3-AF82-42F9-8552-D5A9BC1C01A5Q36803937-FCE2BDEF-C5D8-48A1-9A22-86509EC134BEQ37333942-74D377AD-F9A6-4972-9A49-4A860423114EQ37393018-8F517C16-66DC-4D21-B258-DA4AC23DCE28Q37675397-7AE17F73-5B17-4E3E-B58B-C0F357CF2E5FQ37778829-9659331B-4EED-4252-972C-DADCA92EE126Q38514270-B6945160-683E-48F3-9312-5369C8BAB477Q38994980-EBCF1F80-71E3-45A0-9B10-4421F6C541A2
P2860
description
1998 nî lūn-bûn
@nan
1998 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
name
Trial of oral miltefosine for visceral leishmaniasis
@ast
Trial of oral miltefosine for visceral leishmaniasis
@en
Trial of oral miltefosine for visceral leishmaniasis
@nl
type
label
Trial of oral miltefosine for visceral leishmaniasis
@ast
Trial of oral miltefosine for visceral leishmaniasis
@en
Trial of oral miltefosine for visceral leishmaniasis
@nl
prefLabel
Trial of oral miltefosine for visceral leishmaniasis
@ast
Trial of oral miltefosine for visceral leishmaniasis
@en
Trial of oral miltefosine for visceral leishmaniasis
@nl
P2093
P1433
P1476
Trial of oral miltefosine for visceral leishmaniasis
@en
P2093
A K Mandal
F Rosenkaimer
H W Murray
M K Makharia
P304
P356
10.1016/S0140-6736(98)04367-0
P407
P50
P577
1998-12-05T00:00:00Z